J. Weber

Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitors.

E. Stoelben, J. Wolf, R. Riedel, 2022, European journal of cancer.

Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.

J. Wolf, R. Riedel, R. Büttner, 2020, Lung cancer.

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

Roman K. Thomas, V. Walter, Filippo Beleggia, 2017, Scientific Reports.

Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer

Roman K. Thomas, D. Planchard, M. Peifer, 2021, npj Precision Oncology.

FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

R. Riedel, M. Sos, J. Wolf, 2021 .

Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer

Roman K. Thomas, V. Walter, R. Büttner, 2017, Scientific Reports.

Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion-Positive Pancreatic Adenocarcinoma: A Case Report.

T. Zander, J. Wolf, R. Riedel, 2023, JCO Precision Oncology.